Movement Disorder News and Research

Latest Movement Disorder News and Research

ENS, SSIF announce prestigious award to recognize excellence in medical education

Serono Symposia International Foundation (SSIF) has announced today a public competition for an Award to recognise an expert in the field of neurology who has made a significant contribution to medical education activities through research and dedication.

30 May 2011

Omeros' PDE7 program expands addiction franchise

Omeros Corporation today announced that its phosphodiesterase 7 inhibitors demonstrated robust efficacy in animal models of nicotine addiction.

6 May 2011

Scripps Research receives CIRM grant for new research in stem cell biology and disease origins

Stem cells have huge potential in medicine because they have the ability to change or differentiate into many different cell types potentially providing a source of cells to replace those that have been permanently lost by a patient.

6 May 2011

AAN, PDF honor Boston researcher with Clinician Scientist Development Award

A clinician scientist at Massachusetts General Hospital in Boston is receiving $240,000 to further his research into how stem cells may be used to treat Parkinson's disease through the American Academy of Neurology Foundation and the Parkinson's Disease Foundation Clinician Scientist Development Award in Parkinson's Disease Research.

15 Apr 2011

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products.

12 Apr 2011

Study: DBS surgery allows 77% of patients to stop anti-tremor medication use

Deep brain stimulation, a surgical procedure to suppress faulty nerve signals, allowed 77 percent of patients to stop the medications used to treat their essential tremors within one year following the surgery, University of South Florida researchers report.

8 Apr 2011

Workers exposed to welding fumes may face risk of developing brain damage

New research suggests that workers exposed to welding fumes may be at risk for developing brain damage in an area of the brain also affected in Parkinson's disease. The study is published in the April 6, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Apr 2011

Patients with dystonia can benefit from deep brain stimulation therapy

Patients suffering from dystonia, an uncommon yet potentially crippling movement disorder, get better results if they begin deep brain stimulation therapy sooner rather than later, according to an international study published in the March issue of the Journal of Neurology.

30 Mar 2011

Cleveland Medical Devices Inc. spins off Great Lakes NeuroTech

Cleveland Medical Devices Inc. (CMDI) has announced the formation of Great Lakes NeuroTech (www.GLNeuroTech.com), a spin-off company which has acquired the rights to develop, market, and manufacture clinical motor assessment and therapy systems for the movement disorders market as well as physiological monitors for research and education markets. Great Lakes NeuroTech (GLN) will perform R&D, engineering, manufacturing, distribution, and exporting of these technologies through two divisions: Movement Disorders and Research & Education Systems.

28 Mar 2011

University of Aberdeen, TPP enter agreement to develop novel future medicines

TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.

28 Mar 2011

New discovery may improve cochlear implants for deafness

University of Utah scientists used invisible infrared light to make rat heart cells contract and toadfish inner-ear cells send signals to the brain.

28 Mar 2011

Parkinson's disease drugs may lead to impulse control disorders

Mayo Clinic researchers found that dopamine agonists used in treating Parkinson's disease result in impulse control disorders in as many as 22 percent of patients.

25 Mar 2011

Dopamine agonists used in treatment of Parkinson's disease may lead to impulse control disorders

Mayo Clinic researchers found that dopamine agonists used in treating Parkinson's disease result in impulse control disorders in as many as 22 percent of patients.

24 Mar 2011

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

A multi-center gene therapy trial for patients with advanced Parkinson's disease demonstrated reduced symptoms of the progressive movement disorder, according to a new study published in Lancet Neurology.

17 Mar 2011

65-year-old woman receives new neurostimulator implant for deep brain stimulation therapy

A 65-year-old woman with Parkinson's disease became the first patient in the United States to receive a new device for deep brain stimulation (DBS) therapy.

17 Mar 2011

Gene therapy holds promise for Parkinson's treatment

A first-of-its-kind study of gene therapy in the treatment of Parkinson's disease determined that half of all patients who received the treatment had "clinically meaningful improvements" of their symptoms within six months of surgery.

17 Mar 2011

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Neurologix, Inc., announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease were published in an online-first edition of The Lancet Neurology.

17 Mar 2011

Medtronic introduces Activa SC deep brain stimulation system in the U.S. and Europe

With the first U.S. implant of its new Activa SC neurostimulator for deep brain stimulation therapy, Medtronic, Inc. today announced the technology's commercial availability throughout the United States and Europe.

17 Mar 2011

Omeros fourth quarter net loss increases to $7.2 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010.

15 Mar 2011

Positive top-line results from IPX066 Phase III study in patients with PD

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced statistically significant, positive, top-line results of the ADVANCE-Parkinson's Disease Phase III clinical study of the safety and efficacy of IPX066 versus immediate-release carbidopa-levodopa in advanced PD patients experiencing motor fluctuations.

15 Mar 2011